Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning.

Journal: The European respiratory journal
PMID: 31537702

Abstract

BACKGROUND: The role of macrolide/β-lactam combination therapy in community-acquired pneumonia (CAP) of moderate severity is a matter of debate. Macrolides expand the coverage to atypical pathogens and attenuate pulmonary inflammation, but have been associated with cardiovascular toxicity and drug interactions. We developed a decision tree based on aetiological and clinical parameters, which are available to support a personalised decision for or against macrolides for the best clinical outcome of the individual patient.

Authors

  • Rainer König
    Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), Jena University Hospital, D-07747 Jena, Erlanger Allee 101, Germany Network Modeling, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute (HKI) Jena, Beutenbergstrasse 11a, 07745 Jena, Germany Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany rainer.koenig@uni-jena.de.
  • Xueqi Cao
    Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany.
  • Marcus Oswald
    Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), Jena University Hospital, D-07747 Jena, Erlanger Allee 101, Germany Network Modeling, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute (HKI) Jena, Beutenbergstrasse 11a, 07745 Jena, Germany.
  • Christina Forstner
    Institute of Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany.
  • Gernot Rohde
    Dept of Respiratory Medicine, Medical Clinic I, Goethe University Hospital, Frankfurt/Main, Germany.
  • Jan Rupp
    CAPNETZ STIFTUNG, Hannover Medical School, Hannover, Germany.
  • Martin Witzenrath
    CAPNETZ STIFTUNG, Hannover Medical School, Hannover, Germany.
  • Tobias Welte
    CAPNETZ STIFTUNG, Hannover Medical School, Hannover, Germany.
  • Martin Kolditz
    Division of Pulmonology, Medical Dept I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Mathias Pletz
    Institute of Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany mathias.pletz@med.uni-jena.de.

Keywords

External Resources

Popular Topics
Recent Journals